Health AI Central
Share:
Peer-Reviewed Publication
J Med Econ2025;28(1):885-898.December 1, 2025Journal Article

Real-world effectiveness of cariprazine in major depressive disorder and bipolar I disorder in the United States.

Roger S McIntyre1, Mousam Parikh2, Jamie Ta2, Simranpreet Waraich2, Chandra Cohen-Stavi3, Carl Marci3,4, Nadia Nabulsi2
1Department of Psychiatry, University of Toronto, Toronto, Canada.
2AbbVie, North Chicago, IL, USA.
3OM1, Inc., Boston, MA, USA.
4Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
PubMed DOI

Abstract

AIMS: The efficacy of cariprazine for major depressive disorder (MDD) (adjunctive therapy) and bipolar I (BP-I) depression has been demonstrated in clinical trials. This study evaluated the real-world effectiveness of cariprazine in reducing depression severity among patients with moderate-to-severe MDD or BP-I depression. METHODS: Medical/pharmacy claims and electronic medical records (EMRs) fro…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.